Osteoarthritis, Pain
Conditions
Brief summary
Nociceptin/Orphanin is a novel opioid peptide system associated with inflammatory response. Currently is it uncertain as to the presence of absence of nociceptin in synovial fluid of patients. Nociceptin levels will be measured pre-operatively and post-operatively in plasma levels of patients receiving primary total knee arthroplasty. Nociceptin levels will also be measured in synovial fluid levels prior to surgical manipulation.
Detailed description
This is a prospective observational study where nociceptin levels will be drawn from the patient's serum as well as from the patient's synovial fluid. The blood draws will be completed by the anesthesia team and the synovial fluid and tissue will be obtained by the orthopedic team. The initial blood draw will be in the preoperative area and the second blood draw will be five minutes after the release of the tourniquet. The synovial fluid will be drawn by the surgeon with the first incision. There will be no randomization nor control group. Endpoints: 1. The level or absence of nociceptin in synovial fluid in patients receiving total knee primary arthroplasty will be measured via ELISA in picograms per volume. 2. The level or absence of nociceptin in plasma in patients receiving total knee primary arthroplasty both in the preoperative period (less than 1 hour prior to surgery and 5 minutes after the tourniquet is removed) via ELISA in picograms per volume. 3. Determine the changes if any of nociception plasma levels during the perioperative course of patients receiving total primary knee arthroplasty. Secondary Study Endpoints: 1. Determine the effect if present of history of chronic pain and opioid use on the levels of nociception present in patients' synovial fluid and plasma receiving primary total knee arthroplasty. 2. Determine the effect if present of demographic factors on the levels of nociception present in patients' synovial fluid and plasma receiving primary total knee arthroplasty
Interventions
None listed
Sponsors
Milton S. Hershey Medical Center
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
* receiving a primary knee joint arthroplasty by Dr. Davis ages 18-80 years hemodynamically stable no joint or other types of infection informed consent received and signed no prior joint arthroplasty at the current surgical site no other surgical intervention planned
Exclusion criteria
* prior knee arthroplasty at site outside of desired age range pregnant current infection in joint or other location no desire to participate
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Nociceptin in Synovial Fluid | The surgeon will make a small incision after the patient has been anesthetized and prepped and draped. He will then withdraw the synovial fluid and then will begin the surgery after the fluid is removed. | The level or absence of nociceptin in synovial fluid will be measured using ELISA and represented in picograms per volume. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Nociceptin in Plasma | Blood will be drawn in the preoperative period (approximately up to 1 hour prior to surgery). | Determine the presence of absence of nociceptin in plasma in patients receiving total knee primary arthroplasty and determine the changes if any of nociception plasma levels during the perioperative course of patients receiving total primary knee arthroplasty. Nociceptin will be measured using ELISA and represented in terms of picograms per volume. |
| Patient Demographics | Will be determined in the preoperative period up to one hour prior to surgery. | Age |
| Patient Pain Scores | One set of preoperative scores will be obtained up to one hour prior to surgery. | pre-operative pain scores will be determined using the 0-10 verbal analog scale. |
Outcome results
None listed